Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples